Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development is currently focused on four disease targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV).

Recent News

More News >>

Upcoming Events
Monday, May 8, 2017 4:30 p.m. ET
Q2 2017 Enanta Pharmaceuticals Inc Earnings Conference Call

More Events >>

Stock Quote
ENTA (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.19 (0.62%)
Data as of 04/21/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Email Alerts

Sign up to receive email alerts whenever Enanta Pharmaceuticals Inc posts new information to the site.

Just enter your email address and click Submit.
Investor Relations Contact
Carol Miceli
Director, Investor Relations
Enanta Pharmaceuticals, Inc.
Phone: 617-607-0710

Media Relations Contact
Kari Watson
MacDougall Biomedical Communications
Phone: 781-235-3060